Related Experiment Videos
Vitamin D and prostate cancer
D Feldman1, R J Skowronski, D M Peehl
1Department of Medicine, Stanford University School of Medicine, California 94305-5103, USA.
Advances in Experimental Medicine and Biology
|January 1, 1995
Summary
Vitamin D, specifically 1,25-dihydroxyvitamin D [1,25-D], shows potential in treating prostate cancer by inhibiting growth and promoting cell maturation. Further research is warranted to define its therapeutic utility in chemoprevention and differentiation therapy.
Area of Science:
- Oncology
- Endocrinology
- Cell Biology
Background:
- The vitamin D receptor (VDR) is present in prostate cells.
- Vitamin D's role in calcium homeostasis is well-established.
- Emerging evidence suggests vitamin D's influence on cell growth and differentiation.
Purpose of the Study:
- To investigate the presence of VDR in prostate cancer cell lines and primary cultures.
- To examine the bioresponses induced by 1,25-dihydroxyvitamin D [1,25-D] in prostate cells.
- To evaluate the potential of vitamin D as a therapeutic agent for prostate cancer.
Main Methods:
- Detection of VDR in human prostate cancer cell lines.
- Primary cell culture from normal, benign prostatic hyperplasia (BPH), and prostate cancer tissues.
- Treatment of cells with 1,25-D to assess bioresponses.
Main Results:
- VDR was detected in various human prostate cancer cell lines and primary cultures.
- 1,25-D induced significant bioresponses, including growth inhibition and prostate-specific antigen (PSA) stimulation.
- Vitamin D demonstrated anti-proliferative effects and promoted cellular maturation in prostate cells.
Conclusions:
- Vitamin D acts as a crucial cellular modulator of growth and differentiation in prostate cells.
- 1,25-D holds potential for beneficial actions in prostate cancer, possibly in chemoprevention or differentiation therapy.
- Further investigation into vitamin D's therapeutic utility for prostate cancer is warranted.